Mirum Pharmaceuticals (NASDAQ: MIRM) — Perfil da empresa, notícias e dados financeiros
Mirum Pharmaceuticals develops therapies for rare liver diseases through innovative research.
Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ:MIRM) focuses on developing and commercializing a range of therapies aimed at rare and life-threatening liver diseases. Through a combination of innovative research and drug development, the company is dedicated to significantly impacting the lives of patients who have limited treatment options. Their portfolio includes projects at various stages of development, targeting conditions such as Alagille syndrome, Progressive Familial Intrahepatic Cholestasis, and Biliary Atresia among others. Mirum Pharmaceuticals' main objective is to bring transformative treatments to market, improving patient outcomes and quality of life for those affected by these challenging diseases.
Resumo
Operações
Produtos e/ou serviços de Mirum Pharmaceuticals
- Maralixibat for cholestatic pruritus in patients with Alagille syndrome, transforming the treatment of rare pediatric liver diseases.
- LIVMARLI (maralixibat) oral solution, addressing cholestasis in progressive familial intrahepatic cholestasis.
- Volixibat, aimed at treating adults with conditions like primary sclerosing cholangitis, enhancing bile acid management.
- Partnership initiatives to expand maralixibat's global reach, ensuring access to treatments for rare liver conditions.
- Continuous research and development efforts focused on innovative solutions for cholestatic liver diseases.
- Patient support programs designed to provide comprehensive assistance and education to those undergoing treatment for liver conditions.
equipe executiva do Mirum Pharmaceuticals
- Christopher PeetzCEO & Director
- Peter RadovichCOO & President
- Eric H. BjerkholtChief Financial Officer
- Jean-Luc GirardetChief Technical Officer
- Andrew McKibbenSenior Vice President, Strategic Finance & Investor Relations
- Douglas T. SheehyChief Legal Officer & Secretary
- Meredith KiernanSenior Director of Global Corporate Communications
- Erin CampanyChief People Officer
- Lara LongpreChief Development Officer
- Vinita P. KumarSenior Vice President of Quality
Últimas notícias sobre a Mirum Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Mirum Pharmaceuticals, em USD.
- Cap. de mercado
- 5,6 bi
- Receita (TTM)
- 618,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -14.1
- Dividend yield
- —
- Margem de lucro
- -139.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 521,3 mi | -22,1 mi | -23,4 mi | |
| 336,9 mi | -87,6 mi | -87,9 mi | |
| 186,4 mi | -109,2 mi | -163,4 mi | |
| 77,1 mi | -131,2 mi | -135,7 mi |